PRESCIENT THERAPEUTICS LIMITED
ASX:PTXPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 93.2% of what they think they own, once every option and right converts.
Runway under 2 quarters; share count grew 15% in 24 months; 4 cash raises in 24 months
PRESCIENT THERAPEUTICS LIMITED's latest share count, from the ASX market reading in September 2026, stands at 1.14B shares. The company has completed four capital raises in the past 24 months for total proceeds of A$25.8M, the most recent being a combined SPP and Placement in August 2026 raising A$6.0M. Options and rights on issue could convert into 83M new shares, representing a 7.3% overhang; none are currently in the money, and the nearest expiry is November 2026. The company has under 2 quarters of funding at the recent spend rate. No proposed securities issues are currently pending.
Quick answers · 4
When did PTX last raise capital?
The last capital raise in Prescient Therapeutics's filings is SPP and Placement of $6.0M announced 25 Aug 2026, one of 4 cash raises in 24 months.
How much placement capacity does PTX have left?
About 89% of the 15% placement capacity left, about 11% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does PTX have?
In its quarterly cash report for the quarter ended 30 Sept 2026, Prescient Therapeutics reported $5.8M of cash and estimated 1.8 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do PTX's options expire?
Unexercised options and rights equal 7.3% of Prescient Therapeutics's shares on issue; the nearest expiry is Nov 2026.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 30 Sept 2026 | 2A · quoted issue | PTX : ORDINARY FULLY PAID | 1.13B | Appendix 2A |
| 30 Sept 2026 | 2A · quoted issue | PTX : ORDINARY FULLY PAID | 1.07B | Appendix 2A |
| 30 Sept 2026 | 3G · unquoted | PTX : ORDINARY FULLY PAID | 1.05B | Appendix 3G |
| 10 July 2026 | 3H · cancellation | PTX : ORDINARY FULLY PAID | 1.05B | Appendix 3H |
| 19 Dec 2025 | 3G · unquoted | PTX : ORDINARY FULLY PAID | 1.05B | Appendix 3G |
Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (1.13B) need not equal the current count above (1.14B).
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
4 cash raises in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $0.052 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 1.25× today’s price, which takes it to 13.7M (1.2% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| PTXAL | Options | Price-triggered | $0.41 | 4 Nov 2026 | 1.0M | Filing |
| PTXAP | Options | Price-triggered | $0.13 | 15 May 2027 | 1.4M | Filing |
| PTXAQ | Options | Price-triggered | $0.062 | 11 Dec 2028 | 1.4M | Filing |
| PTXAS | Options | Price-triggered | $0.060 | 31 Aug 2029 | 12.3M | Filing |
| PTXAT | Options | Price-triggered | $0.10 | 17 Nov 2029 | 34.7M | Filing |
| PTXAR | Options | Price-triggered | $0.081 | 20 Jan 2030 | 24.0M | Filing |
| — | Options | Price-triggered | $0.098 | 29 Sept 2030 | 8.6M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 30 Sept 2026 | Dr Gavin Shepherd | Buy | 200k | — | — | — | 3Y notice |
| 30 Sept 2026 | James Campbell | Buy entitlement/SPP | 154k | — | — | — | 3Y notice |
| 30 Sept 2026 | Melanie Farris | Buy entitlement/SPP | 77k | — | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.